Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Coupang Inc (CPNG) Price & Performance

BridgeBio Pharma IncTrade
Coupang IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Coupang Inc — how do they compare? BridgeBio Pharma Inc trades at $84.08 (market cap $16.36B), while Coupang Inc trades at $16.49 (market cap $29.66B). The key difference: Coupang Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals.

BBIOCPNG
Market Cap
$16.36B$29.66B
Sector
HealthConsumer Cyclical
52-Week High
$90.17$33.53
52-Week Low
$47.29$15.12
Enterprise Value
$18.14B$29.18B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $83.64, down 1.22% on the day, with a bullish technical signal from moving averages and strong analyst support. Revenue surged to $502.08M in 2025, though net losses widened to -$724.93M, reflecting high R&D spending. Recent news highlights Q2 2026 earnings misses but revenue beats, driven by Attruby sales growth and three late-stage regulatory submissions expected by mid-2027.

Outlook remains optimistic with an 88% buy rating and $104.56 price target, but risks include persistent cash burn, high debt of $1.72B, and negative equity. Key catalysts are FDA decisions in 2027, with success potentially driving significant upside, though failure could exacerbate financial strain.

Coupang Inc

Coupang (CPNG) trades at $16.42, up 1.42% on the day, with technical indicators showing a neutral to bearish bias as the stock consolidates near key support levels. The company reported mixed Q2 2026 results with revenue acceleration but missed earnings expectations, while maintaining strong revenue growth trends and positive operating cash flow of $1.77 billion in 2025. Recent news highlights Coupang's debut on the Fortune Global 500 and ongoing recovery from a data breach incident.

Despite near-term earnings pressure and regulatory challenges, Coupang maintains dominant market position in South Korean e-commerce with expanding Taiwan operations. Wall Street remains overwhelmingly bullish with 87.5% buy ratings and a $23.38 consensus price target representing 42% upside potential, though investors should monitor execution on profitability targets and resolution of the $422 million regulatory fine.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Coupang Inc

Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.

Read more on CPNG